Document is current
Any future updates will be listed below
-
Authors
Bonnefond, Amélie https://orcid.org/0000-0001-9976-3005
Boissel, Mathilde https://orcid.org/0000-0001-5719-8749
Bolze, Alexandre
Durand, Emmanuelle
Toussaint, Bénédicte
Vaillant, Emmanuel
Gaget, Stefan
Graeve, Franck De
Dechaume, Aurélie
Allegaert, Frédéric
Guilcher, David Le
Yengo, Loïc
Dhennin, Véronique
Borys, Jean-Michel
Lu, James T. https://orcid.org/0000-0002-1873-7049
Cirulli, Elizabeth T.
Elhanan, Gai
Roussel, Ronan
Balkau, Beverley
Marre, Michel
Franc, Sylvia
Charpentier, Guillaume
Vaxillaire, Martine
Canouil, Mickaël https://orcid.org/0000-0002-3396-4549
Washington, Nicole L.
Grzymski, Joseph J.
Froguel, Philippe https://orcid.org/0000-0003-2972-0784
- License Information
-
More Information
Article History
Received: 7 May 2020
Accepted: 8 September 2020
First Online: 12 October 2020
Competing interests
: R.R. is an advisory panel member for AstraZeneca, AbbVie, Sanofi, Merck Sharp & Dohme, Eli Lilly, Janssen, Novo Nordisk, Diabnext, Vaiomer and Physiogenex; is a speaker for Bayer and Servier; and has received research funding and provided research support to Danone Research, Amgen, Sanofi and Novo Nordisk. A. Bolze, E.T.C., J.L. and N.L.W. are employees and shareholders of Helix. No other conflicts were reported.
